CEO Corner

CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and challenges that biopharma CEOs and presidents can relate to and should be aware of.  

  • The Case For A Healthcare Futures Market
    The Case For A Healthcare Futures Market

    Now is the time to develop a novel financial instrument which will provide risk transfer, transparency, and more certainty. A futures market in healthcare is a product whose time has come.

  • Understanding The Many Faces Of Innovation
    Understanding The Many Faces Of Innovation

    By its very definition, innovation may travel long and painful paths, require repeated failure, and invite numerous mistakes to gather experience for bringing forward something new. Lady luck also intervenes occasionally, as well.

  • Why More Incentives Are Needed To Tackle Antibiotic Resistance
    Why More Incentives Are Needed To Tackle Antibiotic Resistance

    Antibiotic resistance is a real and immediate threat that is beginning to garner the global attention it needs and deserves. During a meeting of the United Nations in September 2016, the entire General Assembly — 193 nations — reaffirmed its commitment to developing national action plans on combatting antibiotic resistance.

  • An Insider’s View Of Life Outside The Academic Gilded Cage
    An Insider’s View Of Life Outside The Academic Gilded Cage

    There is a lyric from an old Bob Seger song in which the aging songwriter, lamenting the loss of his youthful prowess once filled with vim and vigor, wonders where the time went (“20 years now; where’d they go; 20 years; I don’t know”).

  • Can Financial Markets Solve The Ever-Increasing Costs of Healthcare?
    Can Financial Markets Solve The Ever-Increasing Costs of Healthcare?

    Why hasn't the healthcare industry evolved into vertical segmentation like other industries? Until now, it's because there has been no systematic way to hedge/transfer either institutional or operating risk in the healthcare system because information gathering and delivery is generally limited and poorly organized.

  • Biotechnology: The Hope For Rare Diseases
    Biotechnology: The Hope For Rare Diseases

    John Crowley, chairman and CEO of Amicus Therapeutics discusses why biotechs in the rare disease space face particularly unique and fundamental challenges.

  • Drug Company Discovery & Commercialization: An Election Year Analogy
    Drug Company Discovery & Commercialization: An Election Year Analogy

    As I consider the move from clinical to commercialization, it reminds me of the American electoral system – primary elections that are tightly focused and a general election where a candidate faces a vastly broader audience and has the opportunity to engage on a much larger stage and with far greater impact.

  • The Constant Search For More Efficient Paths To Approval
    The Constant Search For More Efficient Paths To Approval

    There are several general principles that can help accelerate clinical development, beginning and ending with a focus on getting the drug to the patients that need it.

  • Biopharma Companies Are Focused On Access, Continued Innovation
    Biopharma Companies Are Focused On Access, Continued Innovation

    Our shared goal should be to design an economically sustainable system that ensures patient access and promotes future innovation. Here are a few keys to consider as we work toward this goal.

  • In A Political Year, We Need To Remember The Value Of Pharma/Bio
    In A Political Year, We Need To Remember The Value Of Pharma/Bio

    The drug pricing debate has been particularly challenging for our industry, and, with the presidential election coming up, I can’t help feeling that the attacks will only get worse.

More From CEO Corner

LIFE SCIENCE EVENTS

Alice June 26 - 28, 2017
Bangkok, CA
FDA GMP Inspections – Proven Preparation & Survival Techniques June 27, 2017
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
Biomanufacturing Strategy Meeting USA 2017 June 27, 2017
HILTON BOSTON LOGAN AIRPORT, MA
DCAT Sharp Sourcing 2017 June 27, 2017
New Brunswick, NJ
Rational Combinations 360° June 28 - 29, 2017
New York, NY
Clinical Trial Supply Chain Strategy Meeting USA 2017 June 28, 2017
HILTON BOSTON LOGAN AIRPORT, USA, MA
Rational Combinations 360° June 28 - 29, 2017
New York, NY
How To Establish The Number of Runs Required For Process Validation June 28, 2017
1:00 - 2:00 PM EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
12th Annual Conference on Nephrology & Urology 2017 July 6 - 7, 2017
Kuala Lumpur, FL
12th Annual Conference on Nephrology & Urology 2017 July 6 - 7, 2017
Kuala Lumpur, VT
Certified Copies and ALCOA-C: Essentials Post ICH GCP E6 (R2) Addendum July 10, 2017
11:00am- 12:00pm EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
CRO Oversight Post ICH GCP E6 (R2) Addendum July 10, 2017
11:00am- 12:00pm EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
Conducting an Effective GCP Audit of a CRO-Managed Ongoing Study: Tips and Suggestions July 11, 2017
1:00 - 2:30 PM EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Manufacturing & Laboratory Equipment Qualification – Ensuring Bullet-Proof Results July 12, 2017
1:00 - 2:00 PM EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
David Richard July 17 - 18, 2017
Lisbon, AL
Daniel Smith July 20 - 22, 2017
Melbourne, ME
Clinical Study Requirements – Understanding Differences Between the US and EU July 25, 2017
1pm-2:30pm EST, Online Training
Price:  $299 - Includes Bonus Handouts!
NGS and Clinical Applications Congress: USA July 25 - 26, 2017
Philadelphia, PA